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revealed that the cost increased to €255 when the efﬁ-
ciency of empiric treatment rose from 67% to 80% using
a double dose during 8 weeks. The cost related to treat-
ment varied from €112 to €236 using respectively the
cheapest and the most expensive PPI; as compared to the
actual treatment this resulted in a cost decrease of respec-
tively €138 and €233. Number of days treated while on
“on-demand” therapy also signiﬁcantly inﬂuenced costs:
€171 for 1/7 and €270 for 7/7. CONCLUSIONS: The
cost reduction with the new reimbursement proposal is
robust to changes in efﬁciency rate, in PPI-price and in
duration of “on demand” therapy.
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OBJECTIVE: To compare the cost of UK licensed PPI-
based triple therapies for the eradication of H. pylori
from the perspective of the National Health Service.
METHODS: A recent meta-analysis of trials comparing
all UK licensed PPI-based triple therapies using amoxi-
cillin and clarithromycin over a 7-day period found no
signiﬁcant difference in the rate of H. pylori eradication.
Mean per patient costs were calculated by multiplying the
resource utilisation incurred by their respective national
published unit costs at year 2003 prices. To estimate the
impact of using the least expensive triple therapy on a
typical Primary Care Organisation (PCO), differences in
mean per patient cost were multiplied by the annual inci-
dence of H. pylori compared to current expenditure.
Current expenditure was based on national usage pattern
of the available treatment options. Sensitivity analysis
was conducted to assess the impact of administering
omeprazole 40mg once daily vs omeprazole 20mg twice
daily and the availability of generic omeprazole.
RESULTS: Mean per patient cost for a 7-day esomepra-
zole-based treatment regimen was £34.24, £5.03 lower
than omeprazole-, £2.58 less than lansoprazole- and pan-
toprazole-, and £2.13 lower than rabeprazole-based triple
therapies. The budget impact analysis suggests that a
typical PCO could save up to £4386 per annum if only
esomeprazole-based triple therapy were used for H. pylori
eradication. Sensitivity analyses found the results were
robust to changes in key model parameters. CONCLU-
SIONS: Esomeprazole-based triple therapy is the least
expensive treatment option for the eradication of H.
pylori licensed for use in the UK.
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OBJECTIVE: To conduct a cost consequence analysis 
of EnteryxTM procedure versus surgery (Laparoscopic
Nissen Fundoplication = LNF) in a French public hospi-
tal setting. Nissen Fundoplication is the actual technique
of reference for severe Gastro Esophageal Reﬂux Disease
(GERD) and EnteryxTM procedure is a new inject-
able, endoscopic polymer-based treatment for GERD.
METHODS: A decision tree model was built in DATATM
TreeAge 4.0 to predict the average cost and effectiveness
per patient for each of the treatment strategies. The time
horizon was one year and a French public hospital per-
spective was taken. For both strategies, the efﬁcacy crite-
rion was the complete PPI stop after one year. Efﬁcacy
data on EnteryxTM were taken from the EnteryxTM
multicenter clinical trial. Clinical outcomes with LNF
were derived from the literature and validated by a sur-
gical advisory board. Unit cost data were based on the
French DRG system (PMSI 2000). DRG costs have been
inﬂated by 2.5% and 5% to obtain current year costs. 
At 2.5% rate, procedural cost for EnteryxTM were 
estimated at €2200 (based on DRG 830—ambulatory
endoscopy with anaesthesia) and at €6300 for LNF (DRG
215, 216). RESULTS: After one year, the average cost per
patient was lower for EnteryxTM (2.5%: €3364–5%:
€3541) than for Nissen Fundoplication (2.5%: €6492
€–5%: €6800). The one way sensitivity analysis shows
that the model is most sensitive to the success rate of
EnteryxTM and to the procedural cost. CONCLUSION:
For patients eligible for surgery, EnteryxTM offers a new
less invasive and cheaper alternative compared to LNF.
The savings with EnteryxTM are mainly due to lower
hospital and procedural costs.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD)
is one of the most common chronic disorders of the gas-
trointestinal tract. The aim of this study was to evaluate
the cost of illness in patients affected by GERD visited 
by general practitioners (GPs). METHODS: A cross-
sectional observational multicentre cost of illness study
was conducted in the urban area of Milan. Information
was obtained through a battery of four questionnaires
ﬁlled out by 317 GERD patients consecutively enrolled
by 47 GPs, investigating clinical (severity and frequency
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of symptoms), economic (visits, use of drugs, diagnostic
tests, hospitalizations, productivity losses), and quality of
life (EQ-5D and QOLRAD) variables. We evaluated the
costs of the medical resources and the loss of productiv-
ity in the perspective of the society. We report on costs
and EQ-5D. RESULTS: A total of 317 patients were
enrolled, the mean age was 59 years old, and the 58% of
the patients were female. The average cost per patient per
month was €60.95 and drugs accounted for 65% of total
cost. Indirect costs, expressed in terms of days lost at
work or inability to do usual activities, were about 0.5
days per patient. Patients who reported chest pain and
epigastric pain were more costly compared to those 
who did not (P £ 0.01, Mann-Whitney U test). A strong
impairment in the Health Related Quality of Life was also
documented: patients reported an average value 64.4 in
the 0–100 Visual Analogue Scale of EuroQol (EQ-VAS),
signiﬁcantly lower compared to general population. 
The EQ-proﬁle indicated that “pain/disconfort” and
“anxiety/depression” were the most impaired domains.
CONCLUSIONS: This is the ﬁrst Italian study about
costs and HRQol of GERD in which patients are enrolled
by GPs. The study highlights the relevant economic,
social, and quality of life burden of GERD.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD)
is one of the most common chronic disorders of the gas-
trointestinal tract. The aim of the study was to evaluate
the cost of illness and the Health-Related Quality of Life
(HRQoL) in patients with GERD visited by gastroen-
terologists. METHODS: A cross-sectional observational
multicenter cost of illness study was conducted. Patients
were enrolled by gastroenterologists of three specialist
centers in Italy. Information about demographic charac-
teristics, symptoms (frequency and severity), resource use
(visits, drugs, clinical examinations and hospitalizations)
and productivity losses was obtained through an ad 
hoc questionnaire. We evaluated costs of the medical
resources and loss of productivity in the perspective of
the Italian society. To evaluate the HRQoL we used a
battery of two questionnaires (SF-36 and EQ-5D).
RESULTS: Ninety-one patients were enrolled, the mean
age was 52 years old and the 49% of the patients were
males. The average cost per patient-month was €75.42
and hospitalizations accounted for the 34% of total
medical costs. Indirect costs, expressed in terms of lost
productivity, were about 0.2 working days lost per
patient-month. Presence of chest pain and eructation was
associated with higher overall costs (P < 0.05). A strong
impairment in the HRQoL was also documented: SF-36
showed that “role-physical”, “bodily pain” and “role-
emotional” were the most impaired dimensions. These
results are consistent with those obtained with the EQ-
5D proﬁle. Frequency and intensity of symptoms were
signiﬁcantly associated with lower levels of HRQoL.
CONCLUSIONS: This is the ﬁrst study investigating cost
of care and HRQoL of patients with GERD in Italy. The
study highlights the relevant economic, social, and quality
of life burden of GERD.
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OBJECTIVES: Recently published data suggest that an
acceptable threshold of around £30,000 per quality
adjusted life year (QALY) gained is implicitly used in
NICE appraisals on cost-effectiveness of medical inter-
ventions. The objective of this analysis was to investigate
the sensitivity in drug prices during acute treatment of
reﬂux oesophagitis with esomeprazole 40mg or omepra-
zole 20mg by applying a £30,000 threshold in a 
cost-utility analysis. METHODS: Results from a cost-
effectiveness analysis based on clinical study data have
previously been published using a decision analysis model
that considered UK direct medical costs up to 8 weeks.
In the current analysis, this model was modiﬁed to include
utility values associated with having (0.69) or not having
reﬂux oesophagitis (0.84). Utility values were derived
from a recent study using the rating scale method in
patients with gastro-oesophageal reﬂux disease. An addi-
tional analysis was made extending the model to a 16-
week time-frame in order to assess further costs and
effects of achieving treatment success or not during the
initial 8 weeks. Patient management assumptions were
based on a UK physician survey. RESULTS: When the
price of omeprazole was set to zero, the 8-week and 
the 16-week analyses resulted in around £27,700 and
£23,200 per QALY gained respectively by using
esomeprazole treatment. A sensitivity analysis indicated
results below the £30,000 threshold in most combina-
tions of different assumptions and scenarios while
holding the price of omeprazole constant at zero. In the
16-week analysis, esomeprazole treatment remained cost
saving (i.e. esomeprazole provided better effectiveness at
similar or lower costs) when the price of omeprazole was
reduced by around 45%. CONCLUSIONS: Applying an
acceptable threshold of £30,000 per QALY gained in a
cost-utility analysis of esomeprazole versus omeprazole in
the acute treatment of reﬂux oesophagitis indicates that
esomeprazole will remain cost-effective irrespective of
future generic omeprazole prices.
